Generics in Europe

Generics in Europe

Datamonitor's Generics in Europe industry profile is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information.

Scope

* Contains an executive summary and data on value, volume and/or segmentation

* Provides textual analysis of the industry’s recent performance and future prospects

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Includes a five-year forecast of the industry

* The leading companies are profiled with supporting key financial metrics

* Supported by the key macroeconomic and demographic data affecting the market

Highlights

* Detailed information is included on market size, measured by value and/or volume

* Five forces scorecards provide an accessible yet in depth view of the market’s competitive landscape

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The generics market consists of all sales of generic drugs for human use at ex-manufacturer prices. Datamonitor defines a generic as an officially-approved copy of an original product whose patent has expired, marketed either as a brand or using the generic name.

This definition excludes multi-source copy products, that make up much of markets such as India, Spain and Italy. Multi-source copies are drugs still under patent that are offered by manufacturers other than the patent holders. All currency conversions have been calculated at constant 2008 average exchange rates.

For the purpose of this report Europe is deemed to comprise of Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, the Ukraine and the United Kingdom.

The global figure is deemed to comprise of the Americas, Asia-Pacific and Europe.

The Americas comprises Argentina, Brazil, Canada, Chile, Colombia, Mexico, Venezuela, and the US.

Asia-Pacific comprises Australia, China, Japan, India, Singapore, South Korea and Taiwan.

TABLE OF CONTENTS
EXECUTIVE SUMMARY 3
CHAPTER 1 Market Overview 7
1.1 Market Definition 7
1.2 Research Highlights 7
1.3 Market Analysis 8
CHAPTER 2 Market Value 9
CHAPTER 3 Market Segmentation I 10
CHAPTER 4 Market Segmentation II 11
CHAPTER 5 Five Forces Analysis 12
5.1 Summary 12
5.2 Buyer Power 14
5.3 Supplier Power 15
5.4 New Entrants 16
5.5 Substitutes 17
5.6 Rivalry 18
CHAPTER 6 Leading Companies 19
6.1 Teva Pharmaceutical Industries 19
6.2 Ratiopharm Group 23
6.3 STADA Arzneimittel AG 24
6.4 Mylan Laboratories Inc. 26
CHAPTER 7 Market Forecasts 29
7.1 Market Value Forecast 29
CHAPTER 8 Macroeconomic Indicators 30
CHAPTER 9 Appendix 31
9.1 Methodology 31
9.2 Industry Associations 32
9.3 Related Datamonitor Research 32

LIST OF TABLES
Table 1: Europe Generics Market Value: $ billion, 2004-2008 9
Table 2: Europe Generics Market Segmentation I: % Share, by Value, 2008 10
Table 3: Europe Generics Market Segmentation II: % Share, by Value, 2008 11
Table 4: Key Facts: Teva Pharmaceutical Industries 19
Table 5: Key Financials: Teva Pharmaceutical Industries 22
Table 6: Key Facts: Ratiopharm Group 23
Table 7: Key Facts: STADA Arzneimittel AG 24
Table 8: Key Financials: STADA Arzneimittel AG 25
Table 9: Key Facts: Mylan Laboratories Inc. 26
Table 10: Key Financials: Mylan Laboratories Inc. 28
Table 11: Europe Generics Market Value Forecast: $ billion, 2008-2013 29
Table 12: Europe Exchange Rate, 2004-2008 30